Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A

Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by excessive hepatic lipid accumulation. This study evaluated the therapeutic effects and molecular mechanisms of tirzepatide, a dual GIP and GLP-1 receptor agonist, in treating hepatic steatosis. Eight-week-old C57BL/6J mic...

Full description

Saved in:
Bibliographic Details
Main Authors: Yun Li, Wencong Sun, Hong Liu, Xiong Z. Ruan
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2025-11-01
Series:Genes and Diseases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352304225002508
Tags: Add Tag
No Tags, Be the first to tag this record!